IGM Biosciences to Present at Four Upcoming Investor Conferences
IGM Biosciences, a clinical-stage biotechnology firm, announced that CEO Fred Schwarzer will present at four investor conferences in September 2020.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
IGM Biosciences, a clinical-stage biotechnology firm, announced that CEO Fred Schwarzer will present at four investor conferences in September 2020. The conferences include:
- Baird 2020 Global Healthcare Conference on September 9 at 3:10 p.m. ET
- H.C. Wainwright 22nd Annual Global Investment Conference on September 16 at 1:00 p.m. ET
- 2020 Cantor Global Virtual Healthcare Conference on September 17 at 4:40 p.m. ET
- Morgan Stanley 18th Annual Global Healthcare Conference on September 18 at 11:45 a.m. ET
Live webcasts will be available on the company's website with a 90-day archive.
Details
News Market Reaction – IGMS
The recorded move for IGMS in the trading session of this news was +6.57%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MOUNTAIN VIEW, Calif., Sept. 02, 2020 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will present at four upcoming investor conferences:
- Baird 2020 Global Healthcare Conference on Wednesday, September 9 at 3:10 p.m. ET.
- H.C. Wainwright 22nd Annual Global Investment Conference on Wednesday, September 16 at 1:00 p.m. ET.
- 2020 Cantor Global Virtual Healthcare Conference on Thursday, September 17 at 4:40 p.m. ET.
- Morgan Stanley 18th Annual Global Healthcare Conference on Friday, September 18 at 11:45 a.m. ET.
A live webcast of the events will be available on the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investor.igmbio.com/news-and-events/events-and-presentations. A replay of the webcasts will be archived on the Company’s website for 90 days following the event.
About IGM Biosciences, Inc.
Headquartered in Mountain View, California, IGM Biosciences is a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies. Since 2010, IGM Biosciences has worked to overcome the manufacturing and protein engineering hurdles that have limited the therapeutic use of IgM antibodies. Through its efforts, IGM Biosciences has created a proprietary IgM technology platform for the development of IgM antibodies for those clinical indications where their inherent properties may provide advantages as compared to IgG antibodies.
Contact:
Argot Partners
David Pitts
212-600-1902
igmbio@argotpartners.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.